A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults with Growth Hormone Deficiency

Beckert Michael0 个研究点目标入组 24 人开始时间: 2022年3月5日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. Signing of the trial specific informed consent
•2. Completion of the treatment period and Visit 7 assessments of trial TCH-306, including collection and upload of Visit 7 DXA scan
•3. Fundoscopy at Visit 7 in trial TCH-306 without signs/symptoms of intracranial hypertension or diabetic retinopathy stage 2 / moderate or above

•1. Diabetes mellitus if any of the following are met:
•a. Poorly controlled diabetes, defined as HbA1C higher than 7.5% according to central laboratory at Visit 6 in trial TCH-306
•b. Use of diabetes mellitus drugs other than metformin and/or dipeptidyl peptidase-4 (DPP-4) inhibitors
•2. Active malignant disease or history of malignancy. Exceptions are:
•a. Resection of in situ carcinoma of the cervix uteri
•b. Complete eradication of squamous cell or basal cell carcinoma of the skin
•3. Known history of hypersensitivity and/or idiosyncrasy to the investigational product (somatropin or excipients)
•4. Female who is pregnant, plans to become pregnant, or is breastfeeding
•5. Female participant of childbearing potential (i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile) not willing throughout the trial to use contraceptives as required by local law or practice.
•6. Male participant not willing throughout the trial to use contraceptives as required by local law or practice.
•7. Any disease or condition that, in the judgement of the investigator, may make the participant unlikely to comply with the requirements of the protocol or any condition that presents undue risk from the investigational product or trial procedures

发起方